Download FREE Report Sample
Download Free sampleThe global Coated Endotracheal Tube market was valued at 1647.09 Million USD in 2021 and will grow with a CAGR of 4.62% from 2021 to 2027, based on Research newly published report.
The prime objective of Coated Endotracheal Tube Market is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, Coated Endotracheal Tube Market covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Endotracheal tubes are medical devices used for intubation into the trachea to maintain an open airway and to administer certain drugs. There are used for mechanical ventilation, thus there is risk for microbial invasion into the airways. Therefore, to prevent or reduce the incidence of hospital acquired infection or ventilator-associated pneumonia (VAP), endotracheal tubes are coated with a drug-releasing coating that releases antimicrobial agents to inhibit bacterial growth and biofilm formation. Coated endotracheal tube includes variety of endotracheal tubes coated with drugs or materials, which offer antimicrobial properties to endotracheal tube. Coatings include heparin, silver, chlorhexidine, rifampicin, and minocycline agents.Coated endotracheal tubes are advantageous because coatings have a broad-spectrum antimicrobial activity in vitro, that reduces bacterial adhesion and restricts the biofilm formation on the tube surface. This in turn blocks the occurrence of type of hospital-associated infection called ventilator-associated pneumonia. Ventilator-associated pneumonia (VAP) is a type of infection that mainly occurs in patients with mechanical ventilation and it is caused due to the growth of microorganism on the surface of air management devices, thereby causing illness. According to the infectious diseases society of America/American thoracic society guidelines, 2016, VAP develops 48?72 hours after endotracheal intubation. Moreover, VAP affects 28% of patients who are on mechanical ventilation. Therefore, VAP is an important source of morbidity and mortality in critically ill patients. The mortality rate attributed to VAP is 27% and as high as 43% when the causative agent is antibiotic resistant. Hence, it is important to prevent VAP infections by replacing the non-coated endotracheal tubes with coated endotracheal tubes. Endotracheal tubes if coated with antibiotic agents such as drugs and silver, will prevent the growth of microorganisms during ventilation. Therefore, increase in incidence of VAP is projected to upsurge the need of coated endotracheal tubes, thus boosting the market growth.
By Market Verdors:
By Types:
By Applications:
Key Indicators Analysed
Key Reasons to Purchase
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy